SIRPA and neoplasm: For example, anti-CD47 antibody Hu5F9-G4 has a well-tolerated anti-tumor efficiency both in solid tumors and hematologic tumors [26] Also, the anti-SIRPα antibody is a promising antitumor drug with fewer hematologic toxic side effects because of the confined expression of SIRPα on normal cells compared with CD47 [49].